Enlaza Therapeutics has filed a notice of an exempt offering of securities to raise $61,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Enlaza Therapeutics is raising $61,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sergio Duron played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Enlaza Therapeutics
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
To learn more about Enlaza Therapeutics, visit http://www.enlazatx.com/
Contact:
Sergio Duron, Chief Executive Officer
858-348-2180
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved